|
The future in the present, for a better quality of life
The attention of Bouty to the new technologies is not like a fashion, but it has ever been in the tradition of the company, as a tool to project the future.
For some time, Bouty has pioneered new diagnostic technologies ; an example of which was the BOUTY 1994 acquisition of Technogenetics, that brought know-how suitable for:
- development and production of special monoclonal antibodies
- implementation of DNA recombinant techniques
- molecular investigations
The scientific challenges of the forthcoming era see Bouty prepared to face the international competition: the company is investing substantial resources in the development of new products, PCR based, in the following areas:
- Virology
- Genetics
- Oncovirology
- Immunology
The results of the ongoing developments, combined with the current proven technology, will set an ideal platform that will allow Bouty to play a significant role in the new biotech scenario. |
